201.24
price up icon0.45%   0.735
 
loading
Abbvie Inc stock is traded at $201.24, with a volume of 3.45M. It is up +0.45% in the last 24 hours and down -1.72% over the past month. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$200.50
Open:
$201.05
24h Volume:
3.45M
Relative Volume:
0.49
Market Cap:
$356.05B
Revenue:
$61.16B
Net Income/Loss:
$4.19B
P/E Ratio:
85.22
EPS:
2.3614
Net Cash Flow:
$17.82B
1W Performance:
-3.63%
1M Performance:
-1.72%
6M Performance:
-11.76%
1Y Performance:
+13.76%
1-Day Range:
Value
$200.41
$202.76
1-Week Range:
Value
$199.81
$212.35
52-Week Range:
Value
$176.11
$244.81

Abbvie Inc Stock (ABBV) Company Profile

Name
Name
Abbvie Inc
Name
Phone
(847) 932-7900
Name
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Employee
57,000
Name
Twitter
@abbvie
Name
Next Earnings Date
2026-04-29
Name
Latest SEC Filings
Name
ABBV's Discussions on Twitter

Compare ABBV vs LLY, JNJ, AZN, MRK

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ABBV icon
ABBV
Abbvie Inc
201.30 362.81B 61.16B 4.19B 17.82B 2.3614
LLY icon
LLY
Lilly Eli Co
916.73 806.72B 65.18B 20.64B 5.96B 22.59
JNJ icon
JNJ
Johnson Johnson
231.25 544.73B 96.36B 21.04B 19.70B 8.6488
AZN icon
AZN
Astrazeneca Plc
193.66 303.62B 58.80B 10.24B 8.98B 3.2788
MRK icon
MRK
Merck Co Inc
114.77 278.01B 64.93B 18.26B 12.36B 7.2751

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-21-26 Initiated Canaccord Genuity Buy
Feb-25-26 Initiated RBC Capital Mkts Outperform
Feb-20-26 Initiated Barclays Overweight
Jan-08-26 Downgrade Wolfe Research Outperform → Peer Perform
Jan-07-26 Resumed UBS Neutral
Dec-10-25 Upgrade HSBC Securities Hold → Buy
Nov-13-25 Initiated Scotiabank Sector Outperform
Nov-04-25 Downgrade DZ Bank Buy → Hold
Oct-14-25 Downgrade Erste Group Buy → Hold
Oct-01-25 Downgrade HSBC Securities Buy → Hold
Sep-17-25 Upgrade Berenberg Hold → Buy
Aug-12-25 Resumed Piper Sandler Overweight
Aug-07-25 Upgrade Daiwa Securities Neutral → Outperform
May-14-25 Downgrade Citigroup Buy → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Neutral
Dec-05-24 Downgrade Daiwa Securities Outperform → Neutral
Nov-22-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-04-24 Upgrade Argus Hold → Buy
Oct-17-24 Initiated Bernstein Mkt Perform
Jun-05-24 Upgrade HSBC Securities Hold → Buy
May-17-24 Initiated Cantor Fitzgerald Overweight
Jan-29-24 Upgrade William Blair Mkt Perform → Outperform
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Dec-11-23 Upgrade Goldman Neutral → Buy
Nov-09-23 Initiated Deutsche Bank Hold
Oct-30-23 Upgrade Barclays Equal Weight → Overweight
Oct-20-23 Resumed UBS Neutral
Sep-29-23 Initiated Raymond James Outperform
Jul-25-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Buy
Apr-05-23 Downgrade Argus Buy → Hold
Mar-01-23 Initiated Guggenheim Buy
Feb-22-23 Downgrade Wolfe Research Outperform → Peer Perform
Feb-10-23 Upgrade SVB Securities Underperform → Market Perform
Nov-18-22 Initiated Credit Suisse Outperform
Nov-08-22 Downgrade Societe Generale Buy → Hold
Aug-01-22 Downgrade Atlantic Equities Overweight → Neutral
May-23-22 Initiated SVB Leerink Underperform
May-06-22 Downgrade Daiwa Securities Outperform → Neutral
Apr-06-22 Resumed Morgan Stanley Overweight
Feb-28-22 Downgrade UBS Buy → Neutral
Feb-03-22 Reiterated BMO Capital Markets Outperform
Feb-03-22 Reiterated Barclays Equal Weight
Feb-03-22 Reiterated BofA Securities Neutral
Feb-03-22 Reiterated Goldman Neutral
Jan-13-22 Initiated Redburn Buy
Jan-12-22 Reiterated BMO Capital Markets Outperform
Dec-09-21 Resumed Wells Fargo Overweight
Nov-23-21 Upgrade Societe Generale Hold → Buy
Jul-27-21 Resumed Truist Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Jun-23-20 Upgrade Atlantic Equities Neutral → Overweight
Jun-09-20 Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20 Upgrade Argus Hold → Buy
May-18-20 Resumed BofA/Merrill Neutral
May-12-20 Upgrade JP Morgan Neutral → Overweight
May-11-20 Resumed Morgan Stanley Overweight
Apr-20-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Dec-26-19 Reiterated Cowen Outperform
Sep-26-19 Upgrade Citigroup Neutral → Buy
Aug-20-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-27-19 Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19 Upgrade SVB Leerink Mkt Perform → Outperform
May-28-19 Initiated Goldman Neutral
Apr-29-19 Upgrade BMO Capital Markets Underperform → Market Perform
View All

Abbvie Inc Stock (ABBV) Latest News

pulisher
08:55 AM

AbbVie Announces $1.4B Investment in North Carolina - Contract Pharma

08:55 AM
pulisher
08:00 AM

AbbVie to invest $1.4bn in North Carolina manufacturing campus - The Manufacturer

08:00 AM
pulisher
07:23 AM

AbbVie price target lowered to $294 from $299 at Piper Sandler - TipRanks

07:23 AM
pulisher
06:38 AM

AbbVie opts for North Carolina to house $1.4bn manufacturing site - Pharmaceutical Technology

06:38 AM
pulisher
05:37 AM

ABBV (AbbVie Inc.) posts narrow Q4 2025 EPS beat, shares dip slightly in daily trading.Earnings Volatility - Cổng thông tin điện tử Tỉnh Sơn La

05:37 AM
pulisher
04:56 AM

AbbVie to invest $1.4 billion in NC facility - The Pharma Letter

04:56 AM
pulisher
04:45 AM

$1.4Bn AbbVie Manufacturing Campus Announced for Durham, North Carolina - Construction Review

04:45 AM
pulisher
02:36 AM

AbbVie (ABBV): The Best Stock to Buy on a Pullback - Yahoo Finance

02:36 AM
pulisher
Apr 22, 2026

Spotting Winners: AbbVie (NYSE:ABBV) And Therapeutics Stocks In Q4 - The Globe and Mail

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie becomes 8th of top 10 pharmaceutical manufacturers in North Carolina - The Center Square

Apr 22, 2026
pulisher
Apr 22, 2026

Does AbbVie’s Durham AI Plant and Ovarian Cancer Data Reframe the Bull Case for ABBV? - Yahoo Finance

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development - Insider Monkey

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie Invests $1.4 Billion in New Manufacturing Facility - GuruFocus

Apr 22, 2026
pulisher
Apr 22, 2026

ABBV (AbbVie Inc.) edges past Q4 2025 EPS estimates, posts 8.6 percent revenue growth, shares dip 0.88 percent. - Cổng thông tin điện tử tỉnh Lào Cai

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie | Pharmaceutical company to build new campus in North Carolina, bring hundreds of jobs to Durham - ABC11 Raleigh-Durham

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie To Build Durham Campus, 730 Jobs - Hoodline

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie (ABBV) Stock Jumps On $1.4 Billion North Carolina Campus Announcement - MEXC

Apr 22, 2026
pulisher
Apr 22, 2026

Biopharma company AbbVie to create 730 jobs in Durham - WRAL

Apr 22, 2026
pulisher
Apr 22, 2026

Gov. Stein announces AbbVie to build $1.4 billion manufacturing campus in durham - WUNC News

Apr 22, 2026
pulisher
Apr 22, 2026

Pharma giant AbbVie plans $1.4 billion campus near Research Triangle Park - Axios

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie creating 734 jobs with new $1.4 billion Durham County biopharma campus - CBS17.com

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie announces $1.4 billion investment for 185-acre manufacturing campus in North Carolina - marketscreener.com

Apr 22, 2026
pulisher
Apr 22, 2026

Abbvie Announces $1.4 Billion Investment For 185-Acre Manufacturing Campus In North Carolina - TradingView

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie (ABBV) Unveils $1.4B Manufacturing Campus in North Caroli - GuruFocus

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie to add over 700 jobs at new North Carolina campus - FirstWord Pharma

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie to build $1.4B North Carolina plant By Investing.com - Investing.com Canada

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie to build $1.4B North Carolina plant - Investing.com

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie to build $1.4 billion manufacturing campus in North Carolina - marketscreener.com

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus - Investing News Network

Apr 22, 2026
pulisher
Apr 22, 2026

Biopharma company Abbvie to create 730 jobs in Durham - WRAL

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie announces new $1.4B manufacturing campus (ABBV:NYSE) - Seeking Alpha

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie stock moves down with RSI signaling oversold conditions near $204: weekly analysis - Traders Union

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie (ABBV) Earnings Expected to Grow: Should You Buy? - Yahoo Finance UK

Apr 22, 2026
pulisher
Apr 22, 2026

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Apr 22, 2026
pulisher
Apr 22, 2026

How a single word could determine the future of 340B - Modern Healthcare

Apr 22, 2026
pulisher
Apr 22, 2026

Operating cash flow of AbbVie from 2015 to 2025 - Statista

Apr 22, 2026
pulisher
Apr 22, 2026

Assessing AbbVie (ABBV) Valuation After Recent Share Price Softness And Lofty P/E Premium - simplywall.st

Apr 22, 2026
pulisher
Apr 21, 2026

UChicago Medicine marks one-year countdown to opening of AbbVie Foundation Cancer Pavilion | Newswise - Newswise

Apr 21, 2026
pulisher
Apr 21, 2026

ABBV Initiated Coverage by Canaccord Genuity -- Price Target Ann - GuruFocus

Apr 21, 2026
pulisher
Apr 21, 2026

Five High-Dividend Stocks With Yields Above 3%: AbbVie, Shell, and Chevron Top the List - CoinCentral

Apr 21, 2026
pulisher
Apr 21, 2026

AbbVie initiated with a Buy at Canaccord - TipRanks

Apr 21, 2026
pulisher
Apr 21, 2026

Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031Insight on More than 550 Clinical Trials - GlobeNewswire Inc.

Apr 21, 2026
pulisher
Apr 20, 2026

Biologics Market: Share and Outlook Driven by Roche, Amgen, and AbbVie Leading Advanced Therapeutics - openPR.com

Apr 20, 2026
pulisher
Apr 20, 2026

Here's Why AbbVie (ABBV) Fell More Than Broader Market - Yahoo Finance

Apr 20, 2026
pulisher
Apr 20, 2026

AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada - Investing News Network

Apr 20, 2026
pulisher
Apr 20, 2026

AbbVie Sponsors New BioLabs Facility in Toronto - marketscreener.com

Apr 20, 2026
pulisher
Apr 20, 2026

Will AbbVie's Oncology Franchise Weigh on Q1 Top-line Growth? - qz.com

Apr 20, 2026
pulisher
Apr 20, 2026

AbbVie And BioLabs Team Up To Support Life Sciences Innovation In Canada - TradingView

Apr 20, 2026
pulisher
Apr 20, 2026

Why I Can’t Stop Buying AbbVie Stock - Yahoo Finance

Apr 20, 2026
pulisher
Apr 20, 2026

Nxera Pharma Co., Ltd. Reaches Third R&D Milestone Under Collaboration with Abbvie - marketscreener.com

Apr 20, 2026
pulisher
Apr 20, 2026

Nxera to receive $10 million milestone from AbbVie deal - The Pharma Letter

Apr 20, 2026

Abbvie Inc Stock (ABBV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
AZN AZN
$193.50
price down icon 0.78%
MRK MRK
$114.66
price up icon 1.57%
NVS NVS
$147.30
price down icon 0.00%
$349.45
price up icon 0.91%
NVO NVO
$38.25
price down icon 2.29%
Cap:     |  Volume (24h):